Updated Overall Survival (Os) Results Of Randomized Phase Iii Trial Of Erlotiniti (E) Versus (V) Docetaxel (D) As Second- Or Third-Line Therapy In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc): Docetaxel And Erlotinib Lung Cancer Trial (Delta)

e19003 Background: The DELTA study demonstrated that there was no significant difference in PFS between D and E arms in epidermal growth factor receptor (EGFR)-unselected NSCLC, while D was better than E in EGFR wild type tumors. (Kawaguchi et al., JCO in press). This report represents the final OS results. Methods: OS was re-evaluated using updated data (data cutoff, 31 October, 2013, median follow-up, 12.7 months [interquartile range, 7.0-23.3]) for 301 patients. This study was sponsored by the Japanese National Hospital Organization. Results: A total of 232 events occurred (77.1 %). Median OS for E v D were 13.8 m (95% CI: 9.0-17.8) v 12.3 m (9.7-15.2) in patients with EGFR-unselected tumor [log-rank P = .934; HR = 0.989, 95% CI: 0.764-1.280], and 9.0 m (7.3-13.8) v 10.3 m (7.3-12.4) in patients with EGFR wild type tumor [P = .949; HR = 1.010, 95% CI: 0.742-1.379], respectively. The number of patients who received any post-study treatment was 106 (70.1 %) in E group and 96 (63.6 %) in D group (P = .220...